DaVita Stock Forecast
NYSE: DVAHealth CareMisc Health and Biotechnology ServicesUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
DVA analyst consensus
Consensus (8 analysts)
buy
Avg. price target
$222.29+38.04%
- Strong buy 0
- Buy 3
- Hold 3
- Sell 0
- Strong sell 2
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 8 Wall Street analysts covering DaVita (2026-11-18), 3 rate the stock a buy or strong buy, 3 rate it a hold and 2 rate it a sell or strong sell, for a consensus rating of "buy". The average 12-month price target is $222.29, with a high estimate of $287.00 and a low estimate of $165.00. The average target implies upside of 38.0% from the current price of $161.03.
The spread between the highest and lowest targets is 73.9%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for DVA.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 0 | 0% |
| Buy | 3 | 38% |
| Hold | 3 | 38% |
| Sell | 0 | 0% |
| Strong sell | 2 | 25% |
Ratings as of 2026-11-18.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $165.00 | +2.47% |
| Average target | $222.29 | +38.04% |
| High target | $287.00 | +78.23% |